Last $20.86 USD
Change Today +0.69 / 3.42%
Volume 429.2K
ANAC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Snapshot

Open
$20.23
Previous Close
$20.17
Day High
$21.11
Day Low
$19.89
52 Week High
03/20/14 - $23.07
52 Week Low
08/27/13 - $9.75
Market Cap
876.0M
Average Volume 10 Days
501.2K
EPS TTM
$-0.62
Shares Outstanding
42.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANACOR PHARMACEUTICALS INC (ANAC)

anacor pharmaceuticals inc (ANAC) Related Bloomberg News

View More Bloomberg News

anacor pharmaceuticals inc (ANAC) Related Businessweek News

No Related Businessweek News Found

anacor pharmaceuticals inc (ANAC) Details

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis, and chronic inflammatory skin diseases. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company’s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Schering Corporation, Medicis Pharmaceutical Corporation, Bill and Melinda Gates Foundation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

79 Employees
Last Reported Date: 03/17/14
Founded in 2000

anacor pharmaceuticals inc (ANAC) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $335.0K
Senior Vice President of Program Management
Total Annual Compensation: $330.0K
Senior Vice President of Drug Development
Total Annual Compensation: $272.5K
Senior Vice President of Research
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2013.

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals, Inc. Provides Financial Guidance for the Remainder of the Year 2014

Anacor Pharmaceuticals, Inc. provided financial guidance for the remainder of the year 2014. Contract revenue related to neglected disease partnerships is expected to continue to be approximately $3 million per quarter. Interest expense will continue to be approximately $1.1 million per quarter in 2014. The company currently expects that the company will have at least $110 million in cash at year end 2014.

Anacor Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Anacor Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenue was $2.931 million against $3.424 million a year ago. Loss from operations was $23.425 million against $11.808 million a year ago. Net loss was $24.508 million or $0.58 per diluted share against $14.096 million or $0.36 per diluted share a year ago. The decrease in contract revenues as compared to the same period in 2013 was primarily due to a decrease in revenues from collaborations with Lilly, GlaxoSmithKline LLC and not-for-profit organizations for neglected diseases, partially offset by an increase in revenues for research services performed under contract with the Gates Foundation and the addition of revenues under contract with DTRA, which entered into in the fourth quarter of 2013. For the six months, total revenue was $7.089 million against $5.132 million a year ago. Loss from operations was $43.53 million against $25.975 million a year ago. Net loss was $45.68 million or $109 per diluted share against $29.174 million or $0.78 per diluted share a year ago.

Anacor Pharmaceuticals, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 03:30 PM

Anacor Pharmaceuticals, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-14-2014 03:30 PM. Venue: InterContinental Hotel, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Geoffrey M. Parker, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $20.86 USD +0.69

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings 12.5x
Price/Sales 44.1x
Price/Book 10.0x
Price/Cash Flow 12.4x
TEV/Sales 36.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit www.anacor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.